**** patients enrolled in the HGG 2003 HGG-IMMUNO 2003 trial
Patients, older than 3 and younger than 60 years with relapse of high-grade glioma
(anaplastic astrocytoma WHO grade III or glioblastoma multiforme WHO grade IV),
histologically diagnosed in the first stage of the disease as well as after relapse or
relapse of glioma which was grade II in the First phase but grade III or IV upon relapse
are treated with dendritic cell therapy (immunotherapy) as single treatment approach (No
radiotherapy and/or chemotherapy).
**** patients enrolled in the HGG 2010 HGG-IMMUNO 2010 trial
- prospective double blind placebo controlled randomised clinical trial HGG-2010 for
patients with newly diagnosed glioblastoma in which immunotherapy is integrated in
the current standard of care (concommitant radiochemotherapy).